61results about How to "Safety proof" patented technology

The invention relates to a liposome lyophilized preparation prepared from twelve compound vitamins. The lyophilized preparation is characterized in that the lyophilized preparation is prepared from a liposome which consists of soybean lecithin and glycocholic acid and is encapsulated with twelve vitamins of retinyl palmitate, cocarboxylase tetrahydrate, riboflavin sodium phosphate, pyridoxine hydrochloride, cyanocobalamin, cholecalciferol, ascorbic acid, racemization-alpha tocopherol, D-biotin, niacinamide, folacin and dexpanthenol.

The invention relates to an edaravone lipid microsphere formulation and a preparation method thereof. The edaravone lipid microsphere formulation is prepared by taking the mixed emulsifier of granulesten and poloxamer188 with specific rate as an emulsifier and injection soybean oil as oil phase solvent, and also contains pharmaceutically regular antioxidant. Not only does the prepared edaravone lipid microsphere injection have simple process, low cost and easy industrial production, but also obviously improved stability compared with the existing edaravone injection.

The invention provides a ranitidine hydrochloride lipidosome capsule and new application thereof. Particularly, certain amounts of yolk lecithin, cholesterin, natrium glycocholicum, tween 80 and an active ingredient ranitidine hydrochloride are combined and are prepared into ranitidine hydrochloride lipidosome by film dispersion technology, and the ranitidine hydrochloride lipidosome is mixed with the general accessories of medicine to prepare the capsule. The ranitidine hydrochloride lipidosome capsule better solves the problems of easy deliquescence, moisture absorption, color change and poor stability of the ranitidine hydrochloride, increases preparation medical effect and biological availability and can be used for treating herpetic stomatitis of childrem.

The invention discloses a multi-party quantum digital signature method without a trusted center. The method comprises the following steps: step a, a sender performs operation on an original text to obtain a reduced original text; step b, the sender generates a signature and sends the signature to verification parties separately; step c, each two verification parties exchange the partially owned signature; step d, the sender sends the original text and the signature generated in step b to one verification party; step e, the current verification party performs operation on the received original text to obtain the reduced original text, and performs comparison verification on the signature received from the sender or the previous verification party and the owned signature after the exchange in step c according to each bit of the reduced original text; and after the verification is passed, the other verification parties perform verification in sequence until a preset number of verification parties pass the verification. By adoption of the multi-party quantum digital signature method disclosed by the invention, the problem that a large number of keys are needed in single bit signature is overcome, the multi-party signature demands can be satisfied, and the application scenes are greatly expanded.

The invention relates to a cefixime liposome, a preparation method and a granular formulation containing the cefixime liposome. The granular formulation comprises the cefixime liposome and a pharmaceutically acceptable vector, wherein the cefixime liposome is prepared from the following components in parts by weight: 1 part of cefixime, 1.25-5 parts of hydrogenated soybean lecithin, 1.25-5 parts of hydrogenated egg yolk lecithin, 2.5-10 parts of cholesterol and 0.1-4.5 parts of polysorbate 80. The granular formulation not only accords with the requirement on Chinese pharmacopoeia, but also has the advantages of stabler storage and rapider drug effect exertion and remarkably improved bioavailability compared with the common pharmaceutical cefixime composition at a room temperature.

The invention relates to a cefixime liposome, a preparation method thereof and a dispersible tablet containing the cefixime liposome. The dispersible tablet comprises the cefixime liposome and a pharmaceutically acceptable carrier, wherein the cefixime liposome comprises the following components in parts by weight: 1 part of cefixime, 1.25-5 parts of hydrogenated soybean lecithin, 1.25-5 parts of hydrogenated egg yolk lecithin, 1.25-10 parts of cholesterol and 0.2-3.5 parts of polysorbate 80. The dispersible tablet not only conforms to the requirements of a Chinese pharmacopoeia, but also has the advantages of more stable storage under normal temperature and remarkable improvement of bioavailability compared with the ordinary cefixime medicament composition, and can take effect more rapidly.

It is intended to provide a flavor-improving agent with the use of a starting material that has been taken as a food which can regulate a characteristic smell of a food or a drink. Namely, a composition containing an extract of at least a plant selected from the group consisting of a plant belonging to the genus Crataegus, family Rosaceae, a plant belonging to the genusHouttuynia, family Saururaceae, a plant belonging to the genus Vitis, family Vitaceae, a plant belonging to the genus Anthemis, family Compositae and a plant belonging to the genus Matricaria, family Compositae is provided as aflavor-improving agent for foods and drinks. Either one or two or more kinds of the above-described extracts may be used. As a specific example, it is preferable to use a mixture consisting of the extracts of four kinds of plants as described above.

The invention provides an amoxicillin lipidosome solid preparation and a new application thereof. Certain amounts of yolk lecithin, cholesterin, natrium glycocholicum, tween 80 and an active ingredient amoxicillin are combined and are prepared into amoxicillin lipidosome by film dispersion technology, and the amoxicillin lipidosome is mixed with the certain accessories to prepare various solid preparations. The amoxicillin lipidosome solid preparation not only can solve the problems of poor dissolution rate and poor quality stability of the amoxicillin, increases the medical effect and the bioavailability of the preparation, can treat bacterial liver abscess and obtain good invention effect.

The invention provides a Nimesulide liposome solid preparation and a preparation method of the drug composite thereof. For the Nimesulide liposome solid preparation of the invention, the active ingredient Nimesulide is prepared into liposome and then prepared into Nimesulide solid preparation with other ingredients, wherein the liposome is prepared by the following ingredients according to parts by weight: 1 part of Nimesulide, 3-10 parts of lauric acid glycerol monolaurate, 0.5-4 parts of cholesterol, and 0.1-2 parts of poloxamer188. Compared with the existing Nimesulide liposome solid preparation, the Nimesulide of the invention has high dissolution rate and improved bioavailability, and overcomes the detect that the bioavailability of the Nimesulide liposome solid preparation in the prior art is low.

The invention discloses a freeze-dried preparation of pantoprazole sodium liposomes, wherein pantoprazole sodium is encapsulated in antioxidant-containing liposomes made of soybean lecithin and cholesterol. The freeze-dried preparation is administered intravenously with stable quality, less toxicity and high effectiveness.

The invention relates to an application of a genetic modification stem cell exosome to preparation of medicines or beautifying and whitening cosmetics. miR-27b-3p is used for transfection of epidermalstem cells and an exosome from genetic modification stem cells is obtained. Experiments prove that the exosome can restrain expression of PIK3R3 proteins in melanocyte, can also restrain proliferation and migration of the melanocyte. Safety experiments also prove the safety of the exosome. Therefore, the exosome has good medical and cosmetic application prospects when being made into corresponding medicines or cosmetics.

The invention relates to a loratadine-ambroxol pharmaceutical composite and a liposome solid preparation thereof and a preparation method thereof; the liposome comprises the following components according to the parts by weight percent: 1 part of loratadine, 5 parts of ambroxol hydrochloride, 3-30 parts of yolk lecithin, 1-14 of cholesterol, 1.2-10 parts of sodium deoxycholate and 3-18 parts of poloxamer 188.

The invention relates to a medicine composition containing a pravastatin sodium fenofibrate liposome and a preparation method of the medicine composition. The medicine composition comprises a pravastatin sodium fenofibrate liposome and at least one pharmaceutically acceptable vector, wherein the pravastatin sodium fenofibrate liposome comprises pravastatin sodium, fenofibrate, phospholipid and cholesterol. The medicine composition prepared by the pravastatin sodium fenofibrate liposome not only satisfies the requirements of Chinese Pharmacopoeia and has the advantages of faster dissolution, faster medicine efficacy, high bioavailability, good stability as well as worth of being widely promoted and applied when being compared with the common pravastatin sodium fenofibrate medicine composition.